Precision BioSciences Reports Strong Q4 Profitability, Extends Cash Runway to 2028, and Advances Gene Editing Pipeline

summarizeSummary

Precision BioSciences announced a strong Q4 2025 financial performance with a return to profitability, extended its cash runway through 2028, and reported significant clinical and regulatory advancements across its gene editing programs, including key milestone payments and new patent protection.

check_boxKey Events

• Strong Q4 Financial Results

  The company reported Q4 2025 revenue of $34.2 million, a substantial increase from $0.6 million in Q4 2024, and achieved a net income of $20.1 million ($1.06 per share basic) compared to a net loss of ($17.8) million in the prior year period.

• Extended Cash Runway to 2028

  Following a $75 million financing in November 2025, Precision BioSciences expects its existing cash and equivalents to fund operations through 2028, providing a long runway to achieve multiple clinical inflection points.

• Significant Clinical Progress

  Positive Phase 1 data for PBGENE-HBV showed safety, tolerability, dose-dependent antiviral activity, and molecular evidence consistent with viral DNA gene editing. PBGENE-DMD received IND clearance and Fast Track designation, with initial patient data expected by year-end 2026.

• Strategic Milestone Payments and Partner Confidence

  Precision BioSciences received an $8 million milestone payment from Imugene and a $7.5 million clinical milestone payment from TG Therapeutics, which included TG Therapeutics purchasing 201,504 shares of Precision common stock at $11.17 per share, a significant premium to the current market price.

auto_awesomeAnalysis

Precision BioSciences reported a significant financial turnaround in Q4 2025, achieving net income of $20.1 million compared to a net loss in the prior year, driven by substantial revenue growth. This positive financial performance, combined with a successful $75 million financing in November 2025, has extended the company's cash runway through 2028, significantly de-risking its operations and providing stability for ongoing clinical programs. The filing also highlights substantial progress across its gene editing pipeline, including positive Phase 1 data for PBGENE-HBV with molecular evidence of viral DNA gene editing, and IND clearance with Fast Track designation for PBGENE-DMD, with initial patient data expected by year-end 2026. Furthermore, milestone payments from partners, including TG Therapeutics purchasing company shares at a significant premium to the current market price, underscore external validation of Precision BioSciences' technology and pipeline. The new patent allowances for PBGENE-HBV also provide long-term intellectual property protection.